2.14
8.55%
-0.20
Bio-Path Holdings Inc Aktie (BPTH) Neueste Nachrichten
Bio-Path Holdings, Inc. to Post Q2 2024 Earnings of ($2.06) Per Share, Roth Capital Forecasts (NASDAQ:BPTH) - Defense World
Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Antisense Oligonucleotides Market Comprehensive Analysis: Growing Strategies and Industry Segmentation Fore... - WhaTech
WhaTech
Earnings call: Bio-Path Holdings reports promising Q1 2024 results - Investing.com
Investing.com
Bio-Path: Q1 Earnings Snapshot - Houston Chronicle
Houston Chronicle
Bio-Path Holdings Reports First Quarter 2024 Financial Results - ForexTV.com
ForexTV.com
Bio-Path Holdings Reports First Quarter 2024 Financial Results
GlobeNewswire Inc.
Tesla, Amazon, Microsoft, and other tech giants are spending millions in DC. Here's who is spending the most. - Yahoo News UK
Yahoo News UK
Bio-Path (BPTH) to Release Quarterly Earnings on Wednesday - Defense World
Defense World
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 - ForexTV.com
ForexTV.com
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
GlobeNewswire Inc.
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 - Investing.com South Africa
Investing.com South Africa
Jumia is back, growing total sales and orders in Q1 2024 - Yahoo Singapore News
Yahoo Singapore News
Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com - Defense World
Defense World
Cyclacel Pharmaceuticals (NASDAQ: CYCC) Sees Significant Stock Volatility Amid New Financing Deal - BP Journal
BP Journal
GeneDx Holdings Corp. (WGS) Bolsters Financial and Strategic Position in 2024 - BP Journal
BP Journal
Cutaneous T-Cell Lymphoma (CTCL) Market Size was USD 520 million in 2023, estimates DelveInsight | 4SC, Bio ... - Barchart
Barchart
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Se - Benzinga
Benzinga
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Zacks Investment Research
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket - Adaptive Bio - Benzinga
Benzinga
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire Inc.
Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings
Benzinga
Netflix Adds 9.33 Million Subscribers in Q1, Blowing Past Estimates to Reach Nearly 270 Million Total - Yahoo Movies Canada
Yahoo Movies Canada
Bio-Path Holdings Expands Global Patent Portfolio
GlobeNewswire Inc.
Bio-Path Holdings shares sink 6% after deal for at-the-market offering - MarketWatch
MarketWatch
Bio-Path Holdings Provides 2024 Clinical and Operational Update
GlobeNewswire Inc.
Bio-Path Holdings Announces 2024 Clinical and Operational Progress - TipRanks.com - TipRanks
TipRanks
Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Amidst ... - BP Journal
BP Journal
Mesoblast's (NASDAQ: MESO) Breakthrough: A New Horizon in Pediatric Treatment Sparks Investor Excitement" - BP Journal
BP Journal
Merck Secures FDA Approval for Winrevair, Revolutionizing Treatment for Pulmonary Arterial Hypertension - BP Journal
BP Journal
Bio-Path Holdings faces Nasdaq noncompliance issue - Investing.com India
Investing.com India
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q4 2023 Earnings Call Transcript - Yahoo Finance
Yahoo Finance
Bio-Path Holdings Reports Full Year 2023 Financial Results
GlobeNewswire Inc.
Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie ... - GlobeNewswire
GlobeNewswire
Bio-Path Holdings Announces Consolidating Reverse Stock Split - TipRanks.com - TipRanks
TipRanks
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
GlobeNewswire Inc.
Bio-Path Holdings Approves Reverse Stock Split Vote - TipRanks.com - TipRanks
TipRanks
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
GlobeNewswire Inc.
Antisense Oligonucleotides Industry Poised to Reach US$ 5519.6 Million by 2033-FMI Projection - PharmiWeb.com
PharmiWeb.com
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
GlobeNewswire Inc.
Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Benzinga
Global Small Interfering Rna Sirna Therapeutics Market Future Forecast Analysis Report And Growing Demand 2029 - openPR
openPR
What's Going On With Bio-Path Holdings Stock? - Bio-Path Hldgs (NASDAQ:BPTH) - Benzinga
Benzinga
Marginal Zone Lymphoma Market Size Expected to Demonstrate Optimal Growth in the 7MM During the Study Period ... - GlobeNewswire
GlobeNewswire
Biotech Stocks Take Centerstage as Markets Turn Red (COEP,AMLX, BMRN, EXEL, HALO, INVA, MDXG, INCY, JAZZ ... - BP Journal
BP Journal
Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) Profit Outlook - Yahoo Finance
Yahoo Finance
Prexigebersen–Based Therapy Induces High CR/CRi Rates in Newly Diagnosed, Relapsed/Refractory AML - OncLive
OncLive
Why Is Bio-Path (BPTH) Stock Down 12% Today? - InvestorPlace
InvestorPlace
Bio-Path Holdings Provides Clinical and Operational Update - citybiz
citybiz
Kapitalisierung:
|
Volumen (24h):